MAM
Bols renews deal with Aircel Chennai Open
MUMBAI: BOLS Kyndal, the premium brandy brand has renewed its deal with Aircel Chennai Open 2013 as an Official Partner. This will be the second year of Bols associating with the Aircel Chennai Open.
The 18th edition of the ATP World Tour event will be held from 31 December 2012 – 6 January, 2013 at the SDAT Stadium in Chennai. The tournament will see in action Indian and International players including Tomas Berdych, Janko Tipsarevic, Marin Cilic and Stanislas Wawrinka, who are among the top 20 players in the world.
As part of the association, Bols will host the official Player Party of the tournament.
Bols Kyndal MD Siddharth Banerji said, “We are elated to be associated with the most prestigious sporting event in the country ‘Aircel Chennai Open‘ for second year in the row. With participation from world class players, the tournament will ensure excitement & vibrancy from a wider audience. BOLS as a known brand in the region will strengthen its base & build upon it‘s connect with our connoisseurs.”
IMG Reliance COO Ashu Jindal said,” We are delighted to have a global brand like BOLS associating with Aircel Chennai Open 2013 as the Official Partner. This is the second year of our association and we are excited to have the brand back for another year. We are sure this is just the beginning of yet another successful partnership.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
